Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

作者：Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang, Wei-Zhu Yang, Guowen Yin, Bin‐Yan Zhong, Junhui Sun, Zhi‐Cheng Jin, Jian-Jia Chen, Naijian Ge, Wen‐Bin Ding, Wenhui Li, Jinhua Huang, Wei Mu, Shanzhi Gu, Jiaping Li, Hui Zhao, Shu-Wei Wen, Yanming Lei, Yusheng Song, Chunwang Yuan, Weidong Wang, Ming Huang, Wei Zhao, Jianbing Wu, Song Wang, Xu Zhu, Xu Zhu, Jian-Jun Han, Wei-Xin Ren, Zaiming Lu, Wenge Xing, Yong Fan, Hai-Lan Lin, Zishu Zhang, Wenhao Hu, Qiang Tu, Qiang Tu, Hong-Ying Su, Chuan-Sheng Zheng, Yong Chen, Xuya Zhao, Qi Wang, Qi Wang, Jinwei Zhao, Jian Xu, Jian Xu, Qing-Hua Wu, Huan-Zhang Niu, Jian Wang, Feng Dai, Duiping Feng, Qing-Dong Li, Rong-Shu Shi, Jia-Rui Li, Guang Yang, Hai-Bin Shi, Jian-Song Ji, Yue Liu, Zheng Cai, Po Song Yang, Yang Zhao, Xiao-Li Zhu, Xiao-Li Zhu, Li-Gong Lu, Gao‐Jun Teng, for the CHANCE001 Investigators · 发表于：Signal Transduction and Targeted Therapy · 年份：2023 · DOI：10.1038/s41392-022-01235-0 · 被引用次数：294 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cancer Mechanisms and Therapy、Lung Cancer Treatments and Mutations

There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4-11.0) versus 8.0 months (95% CI, 6.6-9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1-27.3] vs. 15.7 months [13.0-20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P < 0.001). Grade 3/4 adverse events were observed at a rate of 15.8% and 7.5% in combination and monotherapy groups, respectively. Our results suggest that TACE plus PD-(L)1 blockades and MTT could s...